Lv43
715 积分 2020-10-07 加入
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
6小时前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
11小时前
已完结
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
22小时前
已完结
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
1天前
已完结
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial
1天前
已完结
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma
4天前
已完结
Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy
4天前
已完结
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
4天前
已完结
Obinutuzumab for PLA2R-associated membranous nephropathy
4天前
已完结
BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape
5天前
已完结
皖公网安备34019202002308
